On August 7, 2023, Senti Biosciences, Inc. announced Philip Lee, Ph.D., the Company?s Chief Technology Officer, notified the Company of his resignation as an employee and as Chief Technology Officer of the Company, effective on August 7, 2023, to join GeneFab as its Chief Executive Officer. Dr. Lee?s resignation was not the result of any disagreement with the Company on any matter relating to the Company?s operations, policies or practices.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2787 USD | -0.78% | -9.37% | -57.77% |
1st Jan change | Capi. | |
---|---|---|
-57.77% | 13.27M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SNTI Stock
- News Senti Biosciences, Inc.
- Senti Biosciences, Inc. Announces Resignation of Philip Lee as Chief Technology Officer